The upfront combination of VEGF-targeting agents with ICIs is emerging as a therapeutic alternative that could overcome the limitations of IO alone as well as target both the cascade of angiogenesis and the tumor microenvironment (Figure 1). The gene discussed is VEGFA; the disease is neoplasm.